TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A prospective study of 276 patients with HPV-positive oropharyngeal cancer reported 97% five-year locoregional control after treatment that reduced elective nodal radiation to 30 Gy and omitted selected low-risk nodal regions. The findings support further study of de-escalation, but do not establish this regimen as a standard of care; a multicenter phase III trial is needed to confirm it.
A prospective study of 276 people with HPV-positive oropharyngeal cancer found that a reduced-intensity radiation approach was associated with 97% five-year locoregional control, according to results reported in JAMA Oncology. The regimen lowered elective nodal irradiation to 30 Gy and left out selected low-risk lymph-node regions; researchers say the results support further evaluation, not yet routine adoption.
After a median follow-up of five years, 94% of patients had no evidence of disease at five years, and 90.6% were alive at their last follow-up. Reported five-year outcomes included 90.8% overall survival, 85.9% progression-free survival and 91.2% distant metastasis-free survival. These measures describe different outcomes: overall survival tracks whether patients were alive, while the other measures address cancer control or recurrence.
The study’s de-escalation strategy reduced elective nodal irradiation (ENI)—radiation aimed at lymph-node areas considered at risk but not known to contain cancer—to 30 Gy in 15 fractions. The treatment plan also omitted selected low-risk nodal basins. Patients received a sequential boost of 40 Gy in 20 fractions to specified areas. Most were treated with intensity-modulated radiotherapy; 20 received intensity-modulated proton therapy. The study’s authors, led by Nancy Y. Lee of Memorial Sloan Kettering Cancer Center, reported that all patients received concurrent chemotherapy.
There was one elective nodal failure, in a contralateral lymph node that had appeared indeterminate on imaging at baseline and received 30 Gy. The authors reported no failures in the nodal basins omitted from treatment. Most locoregional recurrences occurred where visible residual disease had been present. Distant-only recurrences were reported in 23 patients. At last follow-up, 12 patients were alive without evidence of disease and one was alive with disease.
Lower Radiation to At-Risk Nodes
The findings add long-term follow-up to research into whether some people with HPV-positive oropharyngeal cancer can receive less radiation to surrounding, uninvolved tissue while retaining strong cancer control. Reducing ENI may matter because radiation to areas without known cancer can expose healthy structures involved in saliva production and swallowing. The study did not report quality-of-life outcomes, however, so it cannot show directly whether this particular regimen reduced side effects or improved patients’ daily lives.
David Sher, a radiation oncologist at UT Southwestern Medical Center who was not involved in the study, told MedPage Today that ENI can contribute substantially to normal-tissue exposure. He said the reported results were encouraging, while emphasizing that a multicenter phase III randomized trial is needed to establish whether the approach can match standard treatment across a wider range of settings. The results are not proof that every patient can safely receive less radiation.
Popular right now
Dyson Ball Animal 3 Upright Vacuum – Corded, 290 AW, De‑tangling Motorbar Cleaner Head, 3 Suction Modes
Samsung 65-Inch The Frame Pro Neo QLED 4K TV (2026) Bundle with Modern Brown Bezel, HDMI Cables, and Home Theater Guide
KitchenAid Classic Series 4.5-Quart Tilt-Head Stand Mixer, Onyx Black
As an affiliate, we earn on qualifying purchases.
How the Study Reduced Treatment
The report follows earlier two-year results from the same research group, which showed favorable cancer-control outcomes and what the authors described as excellent quality of life. The new analysis was designed to assess whether those results remained durable with longer observation. The 276 patients received treatment with intensity-modulated radiation therapy or proton therapy alongside concurrent chemoradiation.
The study authors said outcomes were observed across different T- and N-stage groups and smoking histories. Sher pointed to the use of PET-CT imaging for all patients and MRI for most as relevant context: detailed imaging can help clinicians identify lymph nodes that may require higher radiation doses. He also noted that all patients received cisplatin-containing chemotherapy and that the report did not state how many equivocal lymph nodes received a higher dose. Those factors limit how simply the results can be applied to other treatment plans.
“The degree of success is remarkable given the extent of dose reduction.”
— David Sher, UT Southwestern Medical Center, speaking to MedPage Today
Limits Before Routine Adoption
The study reports outcomes from a prospective cohort, but the source material does not describe a randomized comparison of this regimen against standard-dose ENI. It therefore cannot establish from these results alone that reduced-dose treatment is non-inferior to standard treatment. Follow-up was a median of five years, and longer-term outcomes may add information about recurrence and late effects.
It is also unclear from the report how often clinicians increased radiation for equivocal lymph nodes, and this analysis did not provide quality-of-life data. The role of careful imaging and concurrent cisplatin may affect how applicable the results are to patients treated with different imaging, chemotherapy or clinical protocols. The authors’ reported outcomes should not be taken as a recommendation for an individual patient’s treatment.
Testing the Regimen Across Centers
The next major step identified by the study’s outside expert is a multicenter phase III randomized trial to test whether the reduced-dose approach preserves cancer control compared with standard treatment. The source material does not name a trial, provide a launch date or describe a confirmed enrollment plan. Until such evidence is available, the findings are best understood as long-term support for further study rather than a change in established care.
Further research can also clarify how imaging selection, treatment of uncertain lymph nodes, recurrence patterns and quality-of-life outcomes affect the balance between cancer control and treatment burden. Patients considering changes to treatment should discuss their circumstances with their oncology team; this study does not determine an appropriate regimen for any individual.
Key Questions
What treatment approach did the study assess?
It assessed reduced-dose elective nodal irradiation as part of concurrent chemoradiation for HPV-positive oropharyngeal cancer. The approach used 30 Gy for treated nodal and subclinical regions and omitted selected low-risk nodal basins.
What were the main five-year outcomes?
The study reported 97.0% locoregional control, 90.8% overall survival, 85.9% progression-free survival and 91.2% distant metastasis-free survival at five years. The cohort had a median follow-up of five years.
Does the study prove that lower-dose radiation is as effective as standard treatment?
No. The results are encouraging, but the source report says a multicenter phase III randomized trial is needed to confirm non-inferiority. The findings alone do not establish the approach as standard care.
Did the study show fewer side effects or better quality of life?
This long-term report did not provide quality-of-life data, so it does not directly establish whether the regimen reduced side effects. Its authors and an outside expert discussed potential benefits of reducing radiation exposure to healthy structures, but that is not the same as measuring those outcomes in this analysis.
Source: medpagetoday.com
